Advertisement

European Journal of Clinical Pharmacology

, Volume 73, Issue 5, pp 555–562 | Cite as

Pharmacokinetics of a new, nasal formulation of naloxone

  • Ida Tylleskar
  • Arne Kristian Skulberg
  • Turid Nilsen
  • Sissel Skarra
  • Phatsawee Jansook
  • Ola Dale
Pharmacokinetics and Disposition

Abstract

Purpose

Nasal naloxone is wanted for bystander administration in opioid overdose and as a needle-free alternative for emergency medical personnel. Epidemiologic studies have indicated a therapeutic effect of bystander administration of low-concentration/high-volume formulations. The objective for this study was to describe the nasal pharmacokinetics of a new high-concentration/low-volume nasal formulation of naloxone.

Methods

This was an open, randomized triple crossover trial in healthy, human volunteers (n = 12) where two doses of nasal naloxone (0.8 and 1.6 mg) and one intravenous dose (1.0 mg) were compared. Fifteen serum samples were collected before and until 6 h after naloxone administration. Quantification of naloxone was performed by a validated liquid chromatography-tandem mass spectrometry method.

Results

Bioavailability was 0.54 (0.45–0.63) for the 0.8 mg and 0.52 (0.37–0.67) for the 1.6 mg nasal naloxone formulation. Maximum concentration levels (C max) were 1.45 ng/ml (1.07–1.84) for 0.8 mg and 2.57 ng/ml (1.49–3.66) for the 1.6 mg. Time to maximum concentrations (T max) were reached at 17.9 min (11.4–24.5) and 18.6 min (14.4–22.9) for the 0.8 mg and the 1.6 mg doses, respectively.

Conclusion

This nasal naloxone formulation had a rapid, systemic uptake and higher bioavailability than naloxone formulations not designed for IN use. This indicates that an optimized high-concentration/low-volume nasal spray formulation may deliver a therapeutic dose. The 1.6 mg nasal dose provided serum concentrations that surpassed those of 1.0 mg IV after 15–20 min and stayed above for the rest of the study period.

Keywords

Nasal Intranasal Naloxone Pharmacokinetics Bioavailability Overdose 

Notes

Acknowledgements

Thanks to the Unit for Applied Clinical Research, NTNU, for the assistance with GCP monitoring and providing the internet-based randomization, to the Clinical Research Facility, St. Olav’s University Hospital, for conducting the study, and to the Proteomics and Metabolomics Core Facility, PROMEC, NTNU, for conducting the naloxone analysis. These infrastructures are all funded by the Faculty of Medicine, NTNU and the Central Norway Regional Health Authority. We also wish to acknowledge professor Thorsteinn Loftsson, University of Iceland, Reykjavík, Iceland for his valuable advises regarding the formulation. Thanks also to Richard Poulsson, Azanta, Denmark for valuable guidance and genuine interest in the project, and to Inge Christoffer Olsen at ICOStatistics for his aid with the statistical modeling. This study was funded by grants from the Laerdal Foundation for Acute Medicine, Unimed Innovation/St. Olav’s University Hospital and Felles Forskningsutvalg, NTNU/St. Olav’s University Hospital, Norway.

Compliance with ethical standards

Ethical approval and informed consent

All procedures performed in the studies involving human participants were in accordance with the ethical standards of the Helsinki declaration, the principles of the International Conference on Harmonisation, and Good Clinical Practice guidelines. It was approved by the Regional Committee of Medical and Health Research Ethics (2013/1519/REK sør-øst A) and the Norwegian Medicines Agency (EudraCT number: 2013–000050-22) and registered in clinicaltrials.gov (NCT02158117). Informed written consent was obtained from all subjects prior to inclusion. Participants were insured trough the Drug Liability Association, Norway, and compensated for each treatment visit with 1500 NOK (160 Euro/ 175 USD).

Declarations of interest

Ola Dale’s (OD) employer Norwegian University of Science and Technology (NTNU) have recently signed cooperation and licensing contracts with Den norske Eterfabrikk (DnE) to seek commercialization of the nasal naloxone formulation developed by OD. The latter regulates potential royalties for OD through NTNU. OD is engaged by DnE as Principle Investigator in a pharmacokinetic study of naloxone for which OD receives no personal honorarium. DnE has compensated OD for one travel from Trondheim to Oslo.

Arne Kristian Skulberg (AKS) has signed a non-compete contract with DnE lasting the duration of his PhD program at NTNU (estimated 2018). This does not limit AKS right to publish results. AKS will receive no financial benefit from the license agreement between DnE and NTNU. Other authors declare that they have no conflicts of interest.

Supplementary material

228_2016_2191_MOESM1_ESM.docx (140 kb)
ESM 1 (DOCX 140 kb)

References

  1. 1.
    Degenhardt L, Hall W (2012) Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 379(9810):55–70. doi: 10.1016/s0140-6736(11)61138-0 CrossRefPubMedGoogle Scholar
  2. 2.
    Darke S, Mattick RP, Degenhardt L (2003) The ratio of non-fatal to fatal heroin overdose. Addiction 98(8):1169–1171CrossRefPubMedGoogle Scholar
  3. 3.
    Boyer EW (2012) Drug therapy: management of opioid analgesic overdose. N Engl J Med 367(2):146–155CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Health Products Regulatory Authority Naloxone 400 micrograms/ml solution for injection/infusion - Summary of Product Characteristics. http://www.webcitation.org/6g4edopWl Accessed 17/03/2016 2016
  5. 5.
    Clarke SF, Dargan PI, Jones AL (2005) Naloxone in opioid poisoning: walking the tightrope. Emerg Med J 22(9):612–616. doi: 10.1136/emj.2003.009613 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Buajordet I, Naess AC, Jacobsen D, Brors O (2004) Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. Eur J Emerg Med 11(1):19–23CrossRefPubMedGoogle Scholar
  7. 7.
    Kerr D, Kelly AM, Dietze P, Jolley D, Barger B (2009) Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction 104(12):2067–2074. doi: 10.1111/j.1360-0443.2009.02724.x CrossRefPubMedGoogle Scholar
  8. 8.
    Kelly AM, Kerr D, Dietze P, Patrick I, Walker T, Koutsogiannis Z (2005) Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust 182(1):24–27PubMedGoogle Scholar
  9. 9.
    McGregor C, Darke S, Ali R, Christie P (1998) Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. Addiction 93(5):701–711CrossRefPubMedGoogle Scholar
  10. 10.
    World Health Organization (2014) Community management of opioid overdose, WHO guidelines approved by the guidelines review committee. World Health Organization, GenevaGoogle Scholar
  11. 11.
    McDermott C, Collins NC (2012) Prehospital medication administration: a randomised study comparing intranasal and intravenous routes. Emerg Med Int 2012:476161. doi: 10.1155/2012/476161 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Rudd RA, Aleshire N, Zibbell JE, Gladden M (2016) Increases in drug and opioid overdose deaths—United States, 2000–2014. Morbidity and Mortality Weekly Report (MMWR) 64(50–51):1378–1382Google Scholar
  13. 13.
    Hussain A, Kimura R, Huang CH, Kashihara T (1984) Nasal absorption of naloxone and buprenorphine in rats. Int J Pharm 21(2):233–237Google Scholar
  14. 14.
    Ngai SH, Berkowitz BA, Yang JC, Hempstead J, Spector S (1976) Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology 44(5):398–401CrossRefPubMedGoogle Scholar
  15. 15.
    Adapt Pharma (2015) NARCAN® (naloxone hydrochloride) nasal spray - Patient Information Leaflet. http://www.webcitation.org/6g1Upt7eu. Accessed 15 March 2016
  16. 16.
    Dale O, Hoffer C, Sheffels P, Kharasch ED (2002) Disposition of nasal, intravenous, and oral methadone in healthy volunteers. Clin Pharmacol Ther 72(5):536–545. doi: 10.1067/mcp.2002.128386 CrossRefPubMedGoogle Scholar
  17. 17.
    Foster D, Upton R, Christrup L, Popper L (2008) Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother 42(10):1380–1387. doi: 10.1345/aph.1L168 CrossRefPubMedGoogle Scholar
  18. 18.
    Dale O, Nilsen T, Loftsson T, Hjorth Tonnesen H, Klepstad P, Kaasa S, Holand T, Djupesland PG (2006) Intranasal midazolam: a comparison of two delivery devices in human volunteers. J Pharm Pharmacol 58(10):1311–1318. doi: 10.1211/jpp.58.10.0003 CrossRefPubMedGoogle Scholar
  19. 19.
    Dale O, Hjortkjaer R, Kharasch ED (2002) Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 46(7):759–770CrossRefPubMedGoogle Scholar
  20. 20.
    Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC (2007) Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 337(1–2):1–24. doi: 10.1016/j.ijpharm.2007.03.025 CrossRefPubMedGoogle Scholar
  21. 21.
    Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A (2008) Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit 30(4):490–496. doi: 10.1097/FTD.0b013e3181816214 PubMedGoogle Scholar
  22. 22.
    Hertz S (2012) Naloxone for outpatient use: data required to support an NDA. U.S. Food and Drug Administration. http://www.webcitation.org/6kK5i0JH1 Accessed September 6th 2016
  23. 23.
    U.S. Food and Drug Administration (2015) FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose. http://www.webcitation.org/6g1W28jYq Accessed 15/03/2016 2016
  24. 24.
    Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, Aker J, Beck M, Harris J (2016) Pharmacokinetic properties and human use characteristics of an FDA approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol. doi: 10.1002/jcph.759 PubMedGoogle Scholar
  25. 25.
    Kerr D, Dietze P, Kelly AM (2008) Intranasal naloxone for the treatment of suspected heroin overdose. Addiction 103(3):379–386. doi: 10.1111/j.1360-0443.2007.02097.x CrossRefPubMedGoogle Scholar
  26. 26.
    Doe-Simkins M, Walley AY, Epstein A, Moyer P (2009) Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health 99(5):788–791. doi: 10.2105/ajph.2008.146647 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Barton ED, Colwell CB, Wolfe T, Fosnocht D, Gravitz C, Bryan T, Dunn W, Benson J, Bailey J (2005) Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med 29(3):265–271. doi: 10.1016/j.jemermed.2005.03.007 CrossRefPubMedGoogle Scholar
  28. 28.
    Strang J, McDonald R, Tas B, Day E (2016) Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures? Addiction. doi: 10.1111/add.13209 Google Scholar
  29. 29.
    Dadgar D, Burnett PE, Choc MG, Gallicano K, Hooper JW (1995) Application issues in bioanalytical method validation, sample analysis and data reporting. J Pharm Biomed Anal 13(2):89–97CrossRefPubMedGoogle Scholar
  30. 30.
    Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD et al (1991) Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 16(4):249–255CrossRefPubMedGoogle Scholar
  31. 31.
    Middleton LS, Nuzzo PA, Lofwall MR, Moody DE, Walsh SL (2011) The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction 106(8):1460–1473. doi: 10.1111/j.1360-0443.2011.03424.x CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Pires A, Fortuna A, Alves G, Falcao A (2009) Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci 12(3):288–311CrossRefPubMedGoogle Scholar
  33. 33.
    Zuckerman M, Weisberg SN, Boyer EW (2014) Pitfalls of intranasal naloxone. Prehosp Emerg Care 18(4):550–554. doi: 10.3109/10903127.2014.896961 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Robertson TM, Hendey GW, Stroh G, Shalit M (2009) Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehosp Emerg Care 13(4):512–515. doi: 10.1080/10903120903144866 CrossRefPubMedGoogle Scholar
  35. 35.
    Kaléo Pharma (2014) Evzio prescribing information. http://www.webcitation.org/6g1VdDwWl. Accessed 15 March 2016

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Ida Tylleskar
    • 1
  • Arne Kristian Skulberg
    • 1
    • 2
  • Turid Nilsen
    • 1
  • Sissel Skarra
    • 1
  • Phatsawee Jansook
    • 3
  • Ola Dale
    • 1
    • 4
  1. 1.Department of Circulation and Medical ImagingNTNU, Norwegian University of Science and TechnologyTrondheimNorway
  2. 2.Division of Emergencies and Critical Care, Department of AnaesthesiologyOslo University HospitalOsloNorway
  3. 3.Faculty of Pharmaceutical SciencesChulalongkorn UniversityBangkokThailand
  4. 4.Department of Research and DevelopmentSt. Olav’s University HospitalTrondheimNorway

Personalised recommendations